Immunogenicity of Twinrix in older adults: a critical analysis.

Abstract

Twinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) is the first combined vaccine to provide protection against both hepatitis A and B. This review presents a critical analysis of antibody responses stratified by age following vaccination with Twinrix in 264 adults aged above 40 years. A month after completion of a 0-, 1-, 6-month vaccination schedule with Twinrix, a good response was observed for both anti-HAV and anti-HBs serum antibodies, suggesting that is an effective vaccine in older adults.

• Authors: Michel Stoffel, Marc Lievens, Ilse Dieussaert, Isabelle Martin, Francis André
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 2 Issue 1 Pg. 9-14 (Feb 2003) ISSN: 1476-0584 [Print] England
• PMID: 12901592 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Hepatitis A Antibodies
• Hepatitis A Vaccines
• Hepatitis B Antibodies
• Hepatitis B Vaccines
• Vaccines, Combined
• twinrix

Topics

• Adult
• Age Factors
• Aged
• Clinical Trials as Topic
• Comorbidity
• Databases, Factual
• Female
• Hepatitis A Antibodies (biosynthesis, blood)
• Hepatitis A Vaccines (immunology)
• Hepatitis B Antibodies (biosynthesis, blood)
• Hepatitis B Vaccines (immunology)
• Humans
• Immunization Schedule
• Male
• Middle Aged
• Randomized Controlled Trials as Topic
• Retrospective Studies
• Vaccination
• Vaccines, Combined (immunology)